Cerity Partners LLC Has $525.48 Million Holdings in Eli Lilly and Company $LLY

Cerity Partners LLC grew its stake in Eli Lilly and Company (NYSE:LLY) by 13.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 690,583 shares of the company’s stock after purchasing an additional 83,385 shares during the period. Eli Lilly and Company comprises about 0.9% of Cerity Partners LLC’s investment portfolio, making the stock its 19th biggest position. Cerity Partners LLC owned about 0.07% of Eli Lilly and Company worth $525,484,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Braun Bostich & Associates Inc. raised its holdings in Eli Lilly and Company by 2.5% in the 2nd quarter. Braun Bostich & Associates Inc. now owns 527 shares of the company’s stock valued at $411,000 after acquiring an additional 13 shares in the last quarter. Rise Advisors LLC increased its position in shares of Eli Lilly and Company by 1.8% during the second quarter. Rise Advisors LLC now owns 732 shares of the company’s stock valued at $571,000 after purchasing an additional 13 shares during the period. Occidental Asset Management LLC raised its stake in shares of Eli Lilly and Company by 0.7% in the second quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock valued at $1,533,000 after purchasing an additional 13 shares in the last quarter. New Insight Wealth Advisors lifted its position in Eli Lilly and Company by 3.4% in the second quarter. New Insight Wealth Advisors now owns 394 shares of the company’s stock worth $307,000 after purchasing an additional 13 shares during the period. Finally, Dash Acquisitions Inc. boosted its stake in Eli Lilly and Company by 2.8% during the second quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock worth $387,000 after buying an additional 13 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Late‑stage data: Lilly reported a trial where its weight‑loss drug Zepbound plus Taltz improved psoriatic‑arthritis symptoms and produced additional weight loss versus Taltz alone — a clinical win that could expand commercial use and bolster Zepbound’s franchise. Lilly’s Zepbound plus Taltz boosts arthritis relief, weight loss in late-stage trial
• Positive Sentiment: Distribution/DTC reach: Walmart’s new Better Care Services includes LillyDirect as a partner, increasing direct‑to‑consumer visibility and distribution options for Lilly’s digital/patient offerings. Walmart Launches Digital Destination Focused on Health and Wellness
• Positive Sentiment: M&A / diversification: Lilly agreed to buy Ventyx Biosciences for roughly $1.2B to add oral anti‑inflammatory (NLRP3) candidates — a strategic move to diversify beyond GLP‑1 obesity/diabetes products. Eli Lilly to buy Ventyx Biosciences in $1.2 billion deal
• Neutral Sentiment: Analyst/market context: Some firms (e.g., Citigroup, Zacks) still highlight outsized upside for LLY and include it on buy lists, supporting longer‑term bullish views despite short‑term volatility. Eli Lilly Stock (LLY) Has 50% Upside, Says Citigroup
• Negative Sentiment: Legal/regulatory risk: The Indiana attorney general sued Lilly over insulin pricing, a reminder of political and litigation risks around affordability that could pressure sentiment and margins. Indiana attorney general sues Eli Lilly over insulin pricing
• Negative Sentiment: Deal uncertainty: A shareholder investigation into Ventyx’s board over the sale price (and analyst caution about NLRP3 pathway uncertainty) could create noise or drag around the acquisition’s execution and perceived value. SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX)
• Negative Sentiment: Profit‑taking / market rotation: LLY recently hit all‑time highs and led healthcare rallies; today’s pullback looks partly like investors trimming positions and rotating within the sector. Eli Lilly stock hits all-time high

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Leerink Partners set a $1,234.00 price objective on shares of Eli Lilly and Company in a research note on Monday. Weiss Ratings reissued a “buy (b-)” rating on shares of Eli Lilly and Company in a research note on Monday, December 22nd. Morgan Stanley raised their price target on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a research note on Monday, November 24th. National Bankshares set a $1,286.00 price objective on Eli Lilly and Company in a research note on Monday, December 1st. Finally, CICC Research increased their target price on Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a report on Thursday, November 13th. Five equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Buy” and an average price target of $1,169.00.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $1,086.28 on Friday. The stock has a market capitalization of $1.03 trillion, a P/E ratio of 53.14, a price-to-earnings-growth ratio of 0.80 and a beta of 0.35. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The firm has a 50 day moving average of $1,033.14 and a 200-day moving average of $858.57.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business’s revenue was up 53.9% on a year-over-year basis. During the same period last year, the firm posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is currently 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.